Price (delayed)
$10.03
Market cap
$134.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
$131.33M
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a
There are no recent dividends present for GLSI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.